The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Therapy-related AML and MDS: Mutational Profiles Should Determine Treatment Approach
The 58th Annual Meeting & Exposition of the American Society of Hematology (ASH) took place in San Diego, CA, on December 3–6, 2016.
On Sunday 4th December, an educational session was held between 7:30am and 9:00am in the “AML According to WHO: Newer Approaches to Therapy” category. This session was moderated by Jessica K. Altman, MD, of the Northwestern University.
In this session, Michael Heuser, MD, of the Hannover Medical School, Hannover, Germany, gave a presentation titled “Therapy-Related Myeloid Neoplasms: Does Knowing the Origin Help to Guide Treatment?”
In a video interview published on Cancer Network, Michael Heuser discussed his presentation further. He emphasized the effect of genetic mutations on therapeutic options in therapy-related Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Michael Heuser concluded by stating that patients with therapy-related AML and MDS have a worse prognosis and should be treated according to their genetic risk group.
References